ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Hammond Resigns As Director Of USC Comp Center

May 29, 1981

Comprehensive Center NCAB Evaluations

June 2, 1978

Nexon Heads Kennedy Committee Health Staff: Pepper Introduces Bill For May As “NCI Month”

January 16, 1987

Accelerated Approval Will No Longer Block Competitors, FDA Commissioner Says

June 6, 2003

NRC Group Splits Over chemical Dose Testing For Carcinogenicity

March 12, 1993

Drug Development: Herceptin Associated with 15 Deaths, Genentech Says

May 12, 2000